Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew Wang, MD
UNC Lineberger Comprehensive Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rocky Mountain Cancer Center
Denver, Colorado, United States
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- University of North Carolina
Chapel Hill, North Carolina, United States
- Rex Cancer Center at Rex Hospital
Raleigh, North Carolina, United States
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2013
- Primary completion
- 16 Sept 2016
- Completion
- 25 Jun 2019
- Last update posted
- 3 Nov 2020
- Registered enrollment
- 32
- Registry id
- NCT02010567
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.